Clinical Trials Browser

Carcinoma, Renal Cell

Fallopian Tube Neoplasms, Ovarian Neoplasms

Lung Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Lung Neoplasms

Lymphoma, Follicular, Sarcoma, Clear Cell

Uterine Cervical Neoplasms

Carcinoma, Non-Small-Cell Lung

Small Cell Lung Carcinoma

Prostatic Neoplasms

Triple Negative Breast Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Stomach Neoplasms

Small Cell Lung Carcinoma

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Triple Negative Breast Neoplasms

Breast Neoplasms

Triple Negative Breast Neoplasms

Prostatic Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Carcinoma, Hepatocellular, Neoplasms

Breast Neoplasms

Carcinoma, Non-Small-Cell Lung

Pancreatic Adenocarcinoma

Neoplasms, Unknown Primary

Triple Negative Breast Neoplasms

Uterine Cervical Neoplasms

Mesothelioma, Malignant

Breast Neoplasms

Small Cell Lung Carcinoma

Melanoma, Carcinoma, Merkel Cell

Breast Neoplasms, Triple Negative Breast Neoplasms

Brain Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Hepatocellular

Squamous Cell Carcinoma of Head and Neck

Carcinoma, Non-Small-Cell Lung

Advanced Solid Tumor

Breast Neoplasms

Head and Neck Neoplasms, Neoplasms

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Endometrial Neoplasms

Adenocarcinoma, Mucinous, Neoplasm Metastasis, Neoplasms

Recurrent Bladder Urothelial Carcinoma

Solid Tumors

Carcinoma, Hepatocellular

Carcinoma, Transitional Cell, Neoplasm Metastasis, Neoplasms

Clinical Trials

CONTACT-03

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

SKYSCRAPER-04

A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer

IMforte

Abemaciclib With or Without Atezolizumab for mCRPC

Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer

SKYSCRAPER-02C

Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC

A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction

SKYSCRAPER-02

Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

A Study of Tiragolumab in Combination With Atezolizumab in Chemotherapy-Naïve Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

neoMono

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

EL1SSAR

CONTACT-02

Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC

COSMIC-312

Atezolizumab + Stereotactic Radiation in Triple-negative Breast Cancer and Brain Metastasis

A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

CUPISCO

IMpassion132

Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer

Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma

MORPHEUS HR+BC

Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

High-Risk Skin Cancers With Atezolizumab Plus NT-I7

Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer

Testing the Addition of an Anti-cancer Drug, Entinostat, to the Usual Chemotherapy and Immunotherapy Treatment (Atezolizumab, Carboplatin and Etoposide) for Previously Untreated Aggressive Lung Cancer That Has Spread

Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib (G1T28), a CDK4/6 Inhibitor, in Extensive-Stage SCLC

AMETHISTA

A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)

Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor

Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers

KATE3

A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

DEHART

CABATEN

EndoBARR

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer

A Study to Evaluate the Safety and Tolerability of RO7296682 in Combination With Atezolizumab in Participants With Advanced Solid Tumors.

A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

AUREA